MedinCell (ENXTPA:MEDCL) Stock Could Be Overvalued On FDA Approval News

What happened: MedinCell (ENXTPA:MEDCL) drew valuation scrutiny after FDA approval of its long acting injectable olanzapine treatment WELTRUZA and a planned U.S. launch with Teva. Key numbers: 3 year share price gain of about 3.5x. P/S of about 42.6x, versus roughly 2.7x for the wider Pharmaceuticals industry and around 1.7x for closest listed peers. One community narrative puts MedinCell at 18% undervalued. Why it matters: The tailored Fair Ratio framework flags the current P/S as overvalued, with a gap wide enough that the model reads more like a valuation warning than a precise target.

MedinCell (ENXTPA:MEDCL) drew valuation scrutiny after FDA approval of its long acting injectable olanzapine treatment WELTRUZA and a planned U.S. launch with Teva.

The tailored Fair Ratio framework flags the current P/S as overvalued, with a gap wide enough that the model reads more like a valuation warning than a precise target.